Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors

BACKGROUND: Single-agent immunotherapy has shown remarkable efficacy in selected cancer entities and individual patients. However, most patients fail to respond. This is likely due to diverse immunosuppressive mechanisms acting in a concerted way to suppress the host anti-tumor immune response. Comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Borchmann, Sven, Selenz, Carolin, Lohmann, Mia, Ludwig, Hanna, Gassa, Asmae, Brägelmann, Johannes, Lohneis, Philipp, Meder, Lydia, Mattlener, Julia, Breid, Sara, Nill, Marieke, Fassunke, Jana, Wisdom, Amy J., Compes, Anik, Gathof, Birgit, Alakus, Hakan, Kirsch, David, Hekmat, Khosro, Büttner, Reinhard, Reinhardt, H. Christian, Hallek, Michael, Ullrich, Roland T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562723/
https://www.ncbi.nlm.nih.gov/pubmed/36223955
http://dx.doi.org/10.1136/jitc-2022-004781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562723/
https://www.ncbi.nlm.nih.gov/pubmed/36223955
http://dx.doi.org/10.1136/jitc-2022-004781

Ejemplares similares